Washington, D.C. – The Medical Imaging & Technology Alliance (MITA) today applauded Senators Marsha Blackburn (R-TN) and Tammy Baldwin (D-WI) for introducing the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 (S. 2609), which would significantly expand patient access to advanced nuclear diagnostic imaging technologies. This bill mirrors companion legislation already introduced in the House (H.R. 4479).
The legislation addresses structural issues in the packaging methodology used in the Medicare outpatient setting by directing the Department of Health and Human Services (HHS) to pay separately for all diagnostic radiopharmaceuticals with a cost threshold per day of $500. If passed, this bill would give patients greater access to a wide range of diagnostic radiopharmaceuticals that can better detect conditions such as heart disease, Alzheimer's & Parkinson's disease, breast & prostate cancer, and neuroendocrine tumors. This legislation would also help providers better manage costs while delivering more targeted and cost-efficient care.
"Innovative technology like diagnostic radiopharmaceuticals are important tools in detecting and treating diseases such as cancer and Alzheimer's," said Senator Blackburn. "The FIND Act would increase patient access to more cost-effective treatment options while promoting further research and development opportunities for medical manufacturers. I'm pleased to support this effort to improve critical patient care for the Volunteer State."
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
"Advanced nuclear medicine imaging procedures can improve health care outcomes by identifying and diagnosing diseases earlier, when they are most treatable," said Senator Baldwin. "I'm proud to introduce the FIND Act to expand access to this innovative technology and allow more Americans to benefit from earlier and clearer diagnosis so they can better understand their treatment options."
"MITA commends the leadership Senators Blackburn and Baldwin have brought to this issue. Along with Representatives Peters, Rush, Dunn, and Murphy in the House, they are representing a truly nonpartisan issue," said Sue Bunning, MITA Industry Director of Molecular Imaging & PET. "The FIND Act provides a legislative solution to modernize CMS payment policies for PET diagnostic radiopharmaceuticals and expand access. The FIND Act will also encourage innovators, product developers and other interested parties in the medical technology space."
MITA is the collective voice of manufacturers of medical imaging equipment, radiopharmaceuticals, contrast media, and focused ultrasound therapeutic devices. It represents companies whose sales comprise more than 90 percent of the global market for medical imaging innovations. These products include: magnetic resonance imaging (MRI), medical X-Ray equipment, computed tomography (CT) scanners, ultrasound, nuclear imaging, radiopharmaceuticals, and imaging information systems. MITA Member company technologies are an important part of our nation's healthcare infrastructure and are essential for the screening, diagnosis, staging, managing and effectively treating patients with cancer, heart disease, neurological degeneration, and numerous other medical conditions.